In pediatric cases, experimental treatments for this tumor are being explored, including newer therapies such as tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), platelet-derived growth factor receptors (PDGFR α and β), and c-Kit (e.g., Imatinib, Sorafenib, Sunitinib, Pazopanib) [55]. This evidence concerns the gene KIT and neoplasm.